Navigation Links
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Date:6/10/2011

consistent results of improved lung function throughout all six cycles of this study," said Professor Minic.  "In addition, there were no unexpected adverse events associated with the longer term use of the drug.  Taken as a whole, these data indicate that ARIKACE has the potential, if approved, to be an important product for CF patients with Pseudomonas lung infections."  

ARIKACE also demonstrated statistically significant reduction from baseline in Pseudomonas aeruginosa density, including mucoid strains, which was sustained during the treatment and off-treatment periods of the six cycles.  The estimated change from baseline in Log10 CFU over time was -0.6 log (95% CI, -0.2 to -0.9 log; p=0.0030).  Mucoid strains of Pseudomonas are often difficult to suppress with antibiotics and play a significant role in progression of CF lung disease.  In addition, there was no significant shift in the minimum inhibitory concentration (MIC90) of ARIKACE against Pseudomonas over the course of the six cycles, which suggests a lack of resistance development during the study period.

"These results further strengthen the clinical data package Insmed is developing for ARIKACE in the treatment of CF patients," said Renu Gupta, M.D., Executive Vice President Development & Chief Medical Officer of Insmed.  "The data are also indicative of why we are so excited to begin our Phase 3 clinical program in the CF indication, which we expect to initiate in the second half of this year.  For potential registration of ARIKACE in the U.S., we intend to conduct a placebo-controlled clinical trial, and for European registration, we intend to conduct a trial that compares ARIKACE to Novartis Corporation's TOBI®.  Results from these studies are anticipated in the first half of 2013."

"We are pleased that the development of ARIKACE continues to proceed expeditiously," said Robert J.
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
2. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
6. PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
7. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
8. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
9. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
10. Baxa Corporation Demonstrates End-to-End Environmental Stewardship
11. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... N.C. , Aug. 28, 2015  Delays ... research projects can slow down the decision-making process, ... is, therefore, absolutely critical for biopharmaceutical companies to ... research approval process for quicker and more meaningful ... by Best Practices, LLC, nearly three-quarters of benchmarked ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/686gwf/investigation ) ... on China,s Bevacizumab Market ,2010-2019" report to their ... name of Avastin, bevacizumab injection is the first angiogenesis ... approved by CFDA to treat metastatic colorectal cancer. Currently, ... all come from Roche and its subsidiary Genectech. In ...
(Date:8/28/2015)... , Aug. 28, 2015 Patterson ... Inc. (Nasdaq: PDCO ), is now an ... announced acquisition of Patterson Medical by Madison Dearborn ... retain its name for a transition period before ... rehabilitation and sports medicine products.  With the focused ...
Breaking Medicine Technology:Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Bevacizumab Market 2015-2019 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 2Patterson Medical Positioned for Continued Growth as a Newly Independent Company 3
... , ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting 2DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting 3DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting 4DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting 5DUSA Unveils Ergonomic Enhancements to BLU-U(R) at the American Academy of Dermatology Annual Meeting 6PDI Reports 2009 Fourth Quarter and Full Year Financial Results 2PDI Reports 2009 Fourth Quarter and Full Year Financial Results 3PDI Reports 2009 Fourth Quarter and Full Year Financial Results 4PDI Reports 2009 Fourth Quarter and Full Year Financial Results 5PDI Reports 2009 Fourth Quarter and Full Year Financial Results 6PDI Reports 2009 Fourth Quarter and Full Year Financial Results 7PDI Reports 2009 Fourth Quarter and Full Year Financial Results 8PDI Reports 2009 Fourth Quarter and Full Year Financial Results 9PDI Reports 2009 Fourth Quarter and Full Year Financial Results 10PDI Reports 2009 Fourth Quarter and Full Year Financial Results 11PDI Reports 2009 Fourth Quarter and Full Year Financial Results 12PDI Reports 2009 Fourth Quarter and Full Year Financial Results 13PDI Reports 2009 Fourth Quarter and Full Year Financial Results 14PDI Reports 2009 Fourth Quarter and Full Year Financial Results 15PDI Reports 2009 Fourth Quarter and Full Year Financial Results 16PDI Reports 2009 Fourth Quarter and Full Year Financial Results 17PDI Reports 2009 Fourth Quarter and Full Year Financial Results 18PDI Reports 2009 Fourth Quarter and Full Year Financial Results 19PDI Reports 2009 Fourth Quarter and Full Year Financial Results 20PDI Reports 2009 Fourth Quarter and Full Year Financial Results 21PDI Reports 2009 Fourth Quarter and Full Year Financial Results 22PDI Reports 2009 Fourth Quarter and Full Year Financial Results 23PDI Reports 2009 Fourth Quarter and Full Year Financial Results 24PDI Reports 2009 Fourth Quarter and Full Year Financial Results 25PDI Reports 2009 Fourth Quarter and Full Year Financial Results 26PDI Reports 2009 Fourth Quarter and Full Year Financial Results 27PDI Reports 2009 Fourth Quarter and Full Year Financial Results 28PDI Reports 2009 Fourth Quarter and Full Year Financial Results 29PDI Reports 2009 Fourth Quarter and Full Year Financial Results 30PDI Reports 2009 Fourth Quarter and Full Year Financial Results 31
(Date:8/31/2015)... ... August 31, 2015 , ... Now through October 31st, the ... be featured on a digital screen projected above New York’s Times Square, on ... promote earlier awareness of the symptoms of ovarian cancer, and earlier conversations with ...
(Date:8/31/2015)... ... ... All birth control methods work best if used correctly every time you have ... Moreover, no-scalpel vasectomy has many proven advantages with a lower complication rate over the ... are afraid of complications. , One Stop Medical Center reported a zero failure ...
(Date:8/31/2015)... ... ... TheHardwareCity.com is pleased to announce the availability of the technologically-advanced and easy ... are manufactured by Allied Tools. The set consists of a selection of basic tools ... and house work to be completed easily and efficiently without the sacrifice of power ...
(Date:8/30/2015)... ... August 31, 2015 , ... Although middle market companies ... issues that are critically important to them are often overlooked when government sets ... proposed legislation and changing tax and regulatory policies. Smaller companies, which often suffer ...
(Date:8/30/2015)... IL (PRWEB) , ... August 30, 2015 , ... ... is pleased to announce that Partner Daniel M. Kotin was recently elected ... this exclusive organization constitutes the highest degree of peer recognition and outstanding professionalism. ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3
... in the treatment of intestinal disorders for close to ... to be extended to people with rectal cancer. In ... or "hand-assisted" laparoscopic surgery for rectal cancer, a team ... Medical Center has shown that the minimally invasive approach ...
... Nov. 10 Reportlinker.com announces that a ... its catalogue. , Central Nervous ... , http://www.reportlinker.com/p0161866/Central-Nervous-System-Insomnia-or-Sleep-Disorders.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , ... or Sleep Disorders contains detailed information on ...
... at Kickoff Event , HARRISBURG, Pa., Nov. 10 ... in Pennsylvania by urging students to build a rewarding ... , "There will be rising demand for many ... seven years," said Governor Rendell. "During Health Careers Week, ...
... Texas Health Presbyterian Hospital Dallas is the first hospital in ... be named a Cycle III Chest Pain Center by the ... heart attack treatment. , "This honor means that Texas Health ... rapid recognition and collaborative treatment of heart attacks," said cardiologist ...
... Mayo Clinic research studied the association between prostate-specific antigen (PSA) ... of prostate growth is not necessarily a predictor for the ... a man,s PSA level is rising quickly, a prostate biopsy ... findings are being presented this week at the ...
... Medical School estimates 2,266 U.S. military veterans under the age of ... had reduced access to care. That figure is more than 14 ... Afghanistan in 2008, and more than twice as many as have ... 2001. The researchers, who released their analysis today, pointedly say ...
Cached Medicine News:Health News:Minimally invasive surgery shown safe and effective treatment for rectal cancer 2Health News:Minimally invasive surgery shown safe and effective treatment for rectal cancer 3Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 2Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 3Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 2Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 3Health News:Texas Health Dallas Receives Prestigious Chest Pain Accreditation 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 3Health News:Over 2,200 veterans died in 2008 due to lack of health insurance 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: